產(chǎn)品名稱 CCG 232601
產(chǎn)品貨號 Axon 2753 CAS [1922099-21-5] MF C24H20ClF2N3O2MW 455.88 Purity: 99% Soluble in DMSO Description Inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally. KEYWORDS: CCG 232601 | supplier | Rho/MRTF/SRF inhibitor | CCG-232601 | CCG232601 | CAS [1922099-21-5] | Non Selective (Phosphorylation Substrates) | ROCK | Inhibitor | Enzymes | Scleroderma | Sclerosis | Antifibrotic
產(chǎn)品價格 現(xiàn)貨詢價,電話:010-67529703
產(chǎn)品規(guī)格
產(chǎn)品品牌 axonmedchem
產(chǎn)品概述
產(chǎn)品詳情

CCG 232601

Based on 1 reference(s) in Google Scholar 8 10 1

Axon 2753

CAS [1922099-21-5]

MF C24H20ClF2N3O2
MW 455.88

  • Purity: 99%
  • Soluble in DMSO

CCG 232601

Description

Inhibitor of the Rho/MRTF/SRF signaling pathway (IC50 value of 0.55 μM (SRE.L assay)) as potential antifibrotic therapeutic for systemic scleroderma. CCG-232601 inhibited the development of bleomycin-induced dermal fibrosis in mice when administered orally.

KEYWORDS: CCG 232601 | supplier | Rho/MRTF/SRF inhibitor | CCG-232601 | CCG232601 | CAS [1922099-21-5] | Non Selective (Phosphorylation Substrates) | ROCK | Inhibitor | Enzymes | Scleroderma | Sclerosis | Antifibrotic

產(chǎn)品資料